# Exagen (XGN) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/XGN
## Company Profile
- Ticker: XGN
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: Diagnostics, Immunology
## Stock Data
- Close: 6.65 USD
- Market cap: 116450423.98 USD
- Last updated: 2026-08-05
## Business Overview
### Autoimmune Diagnostics
Exagen provides diagnostic testing for autoimmune and rheumatic diseases. Its tests are designed to help clinicians resolve diagnostically complex cases and support ongoing disease management.
### AVISE CTD
AVISE CTD is the company's flagship testing service for lupus and other connective-tissue diseases. It combines multiple biomarkers into an integrated result intended to improve diagnostic confidence. Exagen operates a centralized clinical laboratory and markets its AVISE portfolio primarily to rheumatologists. Revenue is generated through reimbursed testing, supported by payer coverage and physician adoption.
## Why The Stock Is Moving

As of Aug 5, 2026, XGN closed up 3.10% at $6.65. No new same-company headline was identified in the current news window.

## Future Catalysts

- Exagen is heading into a more important stretch around its latest development priorities. Management's latest framing highlights the next company-specific pipeline update. The stock is likely to react most to whether those milestones keep moving without a reset.

## Recent News
- 2026-08-04 12:00 EST — [Exagen Inc. Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/XGN/exagen-inc-reports-second-quarter-2026-financial-results-51c0ee9c) — Source: Exagen
- 2026-07-28 13:00 EST — [Exagen Inc. to Participate in Upcoming Investor Conference](https://biopharmsignal.com/news/XGN/exagen-inc-to-participate-in-upcoming-investor-conference-36ea91ca) — Source: Exagen
- 2026-07-21 13:00 EST — [Exagen to Announce Second Quarter Financial Results on August 4, 2026](https://biopharmsignal.com/news/XGN/exagen-to-announce-second-quarter-financial-results-on-august-4-2026-2e4ac1ee) — Source: Exagen
- 2026-06-01 13:00 EST — [Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus](https://biopharmsignal.com/news/XGN/exagen-announces-publication-of-systematic-review-confirming-robust-real-world-performance-of-avise-lupus) — Source: Exagen
- 2026-05-11 12:00 EST — [Exagen Inc. Reports First Quarter 2026 Results](https://biopharmsignal.com/news/XGN/exagen-inc-reports-first-quarter-2026-results) — Source: Exagen